97
Participants
Start Date
March 31, 2014
Primary Completion Date
January 31, 2016
Study Completion Date
January 31, 2016
Rebif Rebidose
Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
Rebiject II
Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
Research Site, Patchogue
Research Site, Greensburg
Research Site, Dover
Research Site, Winston-Salem
Research Site, Hickory
Research site, Spartanburg
Research Site, Atlanta
Research Site, Miami
Research site, Sunrise
Research site, Cullman
Research Site, Knoxville
Research Site, Dayton
Research Site, Indianapolis
Research site, Golden Valley
Research Site, Oklahoma City
Research site, Mansfield
Research site, Fort Collins
Research Site, Tuscon
Research Site, Newport Beach
Research site, Foxborough
Research Site, Stratford
Lead Sponsor
EMD Serono
INDUSTRY